Results 1 to 10 of about 272 (102)

Calidad de vida de pacientes con tumores cerebrales: panorama actual [PDF]

open access: yesPsicooncologia, 2006
El presente artículo revisa el panorama actual de la calidad de vida en el área de la salud, y de forma específica en tumores cerebrales primarios. Se inicia con una definición y clasificación de los tumores cerebrales de acuerdo a diferentes variables ...
María Eugenia Olivares   +3 more
doaj   +4 more sources

P23.03.A CURRENT PATHWAYS OF REHABILITATION FOR PATIENTS WITH HIGH GRADE GLIOMAS: INSIGHTS FROM AINO (ASSOCIAZIONE ITALIANA DI NEUROONCOLOGIA), SINCH (SOCIETÀ ITALIANA DI NEUROCHIRURGIA) AND SIRN (SOCIETÀ ITALIANA DI RIABILITAZIONE NEUROLOGICA) [PDF]

open access: yesNeuro Oncol
In the management of patients diagnosed with high-grade glioma (HGG), practices and rehabilitation programs display significant variability in real-world settings.
A. Di Stefano   +7 more
europepmc   +2 more sources

Autophagy as a Potential Therapy for Malignant Glioma [PDF]

open access: yesPharmaceuticals, 2020
Glioma is the most frequent and aggressive type of brain neoplasm, being anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), its most malignant forms.
Angel Escamilla-Ramírez   +10 more
doaj   +2 more sources

Presurgical diagnosis of diffuse gliomas in adults:Post-WHO 2021 practical perspectives from radiologists in neuro-oncology units [PDF]

open access: yesRadiología
The 2021 World Health Organization classification of CNS tumours was greeted with enthusiasm as well as an initial potential overwhelm. However, with time and experience, our understanding of its key aspects has notably improved.
Majos, C.   +3 more
core   +5 more sources

Bactericidal/Permeability-Increasing Protein (BPI), a Novel Antimicrobial Molecule in Human Breast Milk with Immune Potential [PDF]

open access: yesMicroorganisms
Breast milk is a fluid of vital importance during the first stages of life of the newborn since, in addition to providing nutrients, it also contains cells and molecules of the immune system, which protect the neonate from infection and, at the same time,
Alba Soledad Aquino-Domínguez   +12 more
doaj   +2 more sources

Lrba participates in the differentiation of IgA+ B lymphocytes through TGFβR signaling [PDF]

open access: yesFrontiers in Immunology
IntroductionLrba is a cytoplasmic protein involved in vesicular trafficking. Lrba-deficient (Lrba-/-) mice exhibit substantially higher levels of IgA in both serum and feces than wild-type (WT) mice.
José Mizael Flores-Hermenegildo   +11 more
doaj   +2 more sources

Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma. [PDF]

open access: yesAJNR Am J Neuroradiol, 2016
Background and purpose: Current protocols in patients with glioblastoma include performing an MR examination shortly after surgery and then 2-6 weeks after ending concomitant chemoradiotherapy. The assessment of this first postradiotherapy examination is
Majós C   +8 more
europepmc   +3 more sources

Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma. [PDF]

open access: yesOxid Med Cell Longev, 2019
Glioblastoma (GBM) is the most common and devastating primary brain tumor. The presence of cancer stem cells (CSCs) has been linked to their therapy resistance.
Hernández-SanMiguel E   +10 more
europepmc   +5 more sources

Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma. [PDF]

open access: yesOncotarget, 2015
Glioblastoma tumor initiating cells are believed to be the main drivers behind tumor recurrence, and therefore therapies that specifically manage this population are of great medical interest.
González-Gómez P   +7 more
europepmc   +6 more sources

Bevacizumab for the treatment of glioblastoma. [PDF]

open access: yesClin Med Insights Oncol, 2013
Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14-15 months and less than 10% of patients will survive 5 years after diagnosis.
Gil-Gil MJ, Mesia C, Rey M, Bruna J.
europepmc   +2 more sources

Home - About - Disclaimer - Privacy